City Therapeutics
City Therapeutics is a biopharmaceutical company focused on harnessing next-generation engineering of small interfering RNAs (siRNAs) to develop innovative RNAi-based medicines. Led by pioneering executives and scientists in RNAi, the company aims to build a sustainable pipeline of therapeutics to impact multiple disease areas and improve patient outcomes. With a mission to unlock the transformative potential of RNAi, City Therapeutics is advancing a pipeline of high-impact medicines and forming strategic collaborations to accelerate development and commercialization.
Industries
Nr. of Employees
small (1-50)
City Therapeutics
Products
RNAi therapeutic pipeline
A proprietary pipeline of engineered RNAi therapeutic candidates based on an siRNA/trigger engineering platform; lead program targeted to enter clinical development at or around year-end 2025 with a planned cadence of one to two INDs per year starting in 2026.
RNAi therapeutic pipeline
A proprietary pipeline of engineered RNAi therapeutic candidates based on an siRNA/trigger engineering platform; lead program targeted to enter clinical development at or around year-end 2025 with a planned cadence of one to two INDs per year starting in 2026.
Services
Collaborative research and licensing agreements to co-develop RNAi triggers and delivery approaches with external biopharma partners; agreements may assign partner responsibility for IND-enabling studies, clinical development and commercialization while the company retains technology rights unless an exclusive license is exercised.
Co-development of RNAi trigger molecules combined with external delivery technologies for central nervous system targets, including partner-managed IND-enabling and clinical development.
Collaborative research and licensing agreements to co-develop RNAi triggers and delivery approaches with external biopharma partners; agreements may assign partner responsibility for IND-enabling studies, clinical development and commercialization while the company retains technology rights unless an exclusive license is exercised.
Co-development of RNAi trigger molecules combined with external delivery technologies for central nervous system targets, including partner-managed IND-enabling and clinical development.
Expertise Areas
- RNAi therapeutics development
- Oligonucleotide chemistry and modification
- Targeted delivery and ligand design
- Clinical development and IND strategy
Key Technologies
- siRNA / oligonucleotide engineering
- Ligand-directed targeted delivery
- Intravitreal (ocular) administration
- Systemic tissue-enhanced delivery
News & Updates
City Therapeutics announced its launch with a $135 million Series A financing led by ARCH Venture Partners, aiming to lead the future of RNAi-based medicine. The company is focused on next-generation engineering of siRNAs to expand therapeutic reach and impact multiple diseases.
John Maraganore, a biotech veteran and co-founder of City Therapeutics, raised $135 million to build the future of RNAi therapeutics, leveraging next-generation engineering technologies.
City Therapeutics launched with a $135 million Series A financing, aiming to lead the next generation of RNAi medicines through innovative engineering and strategic collaborations.
Recent news covering new RNAi startups and advancements in the field, including City Therapeutics' initiatives.
City Therapeutics entered into a strategic collaboration with Bausch + Lomb to develop RNAi therapeutics for retinal diseases including geographic atrophy.
The company appointed Baisong Mei as Chief Medical Officer, Anna O’Driscoll as Chief People Officer, and Sara Nochur as an independent board member.
City Therapeutics announced its launch with a $135 million Series A financing led by ARCH Venture Partners, aiming to lead the future of RNAi-based medicine. The company is focused on next-generation engineering of siRNAs to expand therapeutic reach and impact multiple diseases.
John Maraganore, a biotech veteran and co-founder of City Therapeutics, raised $135 million to build the future of RNAi therapeutics, leveraging next-generation engineering technologies.
City Therapeutics launched with a $135 million Series A financing, aiming to lead the next generation of RNAi medicines through innovative engineering and strategic collaborations.
Recent news covering new RNAi startups and advancements in the field, including City Therapeutics' initiatives.
City Therapeutics entered into a strategic collaboration with Bausch + Lomb to develop RNAi therapeutics for retinal diseases including geographic atrophy.
The company appointed Baisong Mei as Chief Medical Officer, Anna O’Driscoll as Chief People Officer, and Sara Nochur as an independent board member.